GlassScriptPhysician profile
Sidharth R Anand
NPI 1336453810
$16,657.26
in general payments reported to CMS, 2019-2025
13 companies · $5,461 in 2025
The $5,461 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.00 · 2020: $1,137 · 2023: $5,017 · 2024: $4,983 · 2025: $5,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,244 · Consulting Fee: $4,075 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,730 · Travel and Lodging: $1,463 · Food and Beverage: $887 · Education: $61.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,244.00 |
| Consulting Fee | $4,075.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,730.00 |
| Travel and Lodging | $1,463.24 |
| Food and Beverage | $886.65 |
| Education | $61.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $8,111.61 | 2023-2024 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $4,075.00 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $2,890.88 | 2025 | Onivyde |
| Novartis Pharmaceuticals Corporation | $1,136.68 | 2020 | |
| Galvanize Therapeutics, INC | $151.60 | 2023 | Aliya System |
| Ethicon US, LLC | $146.65 | 2025 | Neuwave |
| Alexion Pharmaceuticals, INC. | $60.00 | 2019 | |
| Seagen INC. | $23.29 | 2023 | Tukysa |
| Array Biopharma INC | $23.15 | 2025 | Mektovi, Braftovi, Lorbrena |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $16.40 | 2024 | Fruzaqla |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidharth Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.